Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prophylaxis with vonicog alfa (rVWF) in pediatric severe von Willebrand disease
jRCT2051240117Phase 3Recruiting
- Sponsor
- Takeda
- Start
- Nov 2024
- Modality
- Recombinant Proteins and Enzymes
01
Overview
Phase 3, open-label trial of vonicog alfa in von Willebrand disease (VWD) (3 cohorts), sponsored by Takeda. Primary endpoint: Annualized Bleeding Rate (ABR) for spontaneous or traumatic bleeding episodes. Started Nov 2024; status: recruiting.
02
Drugs
vonicog alfa
03
Conditions
von Willebrand disease (VWD)
Beyond the preview
Go deeper on jRCT2051240117.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051240117.